377 related articles for article (PubMed ID: 11061592)
1. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions.
Sikora J; Dworacki G; Zeromski J
Nat Immun; 1998; 16(5-6):244-55. PubMed ID: 11061592
[TBL] [Abstract][Full Text] [Related]
2. Expression of TCR-zeta chain and apoptosis in subpopulations of tumor-associated lymphocytes (TALs) from malignant pleural effusions.
Sikora J; Zeromski J
Folia Histochem Cytobiol; 2002; 40(4):347-51. PubMed ID: 12502185
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
Shurin GV; Gerein V; Lotze MT; Barksdale EM
Nat Immun; 1998; 16(5-6):263-74. PubMed ID: 11061594
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.
Stewart JH; Nguyen DM; Chen GA; Schrump DS
J Thorac Cardiovasc Surg; 2002 Feb; 123(2):295-302. PubMed ID: 11828289
[TBL] [Abstract][Full Text] [Related]
5. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.
Mantovani G; Macciò A; Versace R; Pisano M; Lai P; Esu S; Ghiani M; Dessì D; Turnu E; Santona MC
J Mol Med (Berl); 1995 Aug; 73(8):409-16. PubMed ID: 8528743
[TBL] [Abstract][Full Text] [Related]
7. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions.
Sikora JJ; Dworacki GT; Kaczmarek MT; Jenek RE; Zeromski JO
Cancer Detect Prev; 2004; 28(5):325-30. PubMed ID: 15542255
[TBL] [Abstract][Full Text] [Related]
9. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
10. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
Siena L; Pace E; Ferraro M; Di Sano C; Melis M; Profita M; Spatafora M; Gjomarkaj M
Immunology; 2014 Feb; 141(2):242-55. PubMed ID: 24128051
[TBL] [Abstract][Full Text] [Related]
12. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo.
Houston A; Waldron-Lynch FD; Bennett MW; Roche D; O'Sullivan GC; Shanahan F; O'Connell J
Int J Cancer; 2003 Nov; 107(2):209-14. PubMed ID: 12949796
[TBL] [Abstract][Full Text] [Related]
13. Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions.
Sikora J; Dworacki G; Trybus M; Batura-Gabryel H; Zeromski J
Tumour Biol; 1998; 19(3):196-204. PubMed ID: 9591046
[TBL] [Abstract][Full Text] [Related]
14. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
[TBL] [Abstract][Full Text] [Related]
15. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
[TBL] [Abstract][Full Text] [Related]
16. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma.
Reichert TE; Strauss L; Wagner EM; Gooding W; Whiteside TL
Clin Cancer Res; 2002 Oct; 8(10):3137-45. PubMed ID: 12374681
[TBL] [Abstract][Full Text] [Related]
17. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas.
Shukuwa T; Katayama I; Koji T
Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
[TBL] [Abstract][Full Text] [Related]
19. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis.
Frei K; Ambar B; Adachi N; Yonekawa Y; Fontana A
J Neuroimmunol; 1998 Jul; 87(1-2):105-13. PubMed ID: 9670851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
